Adjust filters or Reset allto view products Explore the Product Pipeline Take a deep dive into the investigational medicines and vaccines we’re working on. Updated as of February 4, 2025. Leave Help Stay Leave Close BackOverview Development Phase ...
Our ambitions are big and our product pipeline has never been stronger. We’re energized and inspired to apply science and our global resources to develop and deliver breakthrough therapies to people everywhere.To Our Investors Why Invest Financial Reports Events and Presentations Stock Information...
Revolutionary medicines enable us to enrich and extend life for people living with all types of diseases. Rare Disease Internal Medicine Inflammation & Immunology Vaccines Oncology Anti Infectives Pipeline Snapshot as of February 4, 2025 00Phase 1 ...
Revolutionary medicines enable us to enrich and extend life for people living with all types of diseases. Rare Disease Internal Medicine Inflammation & Immunology Vaccines Oncology Anti Infectives Pipeline Snapshot as of February 4, 2025 00Phase 1 ...
Pfizer Pipeline as of September 27, 2010 As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the ...
A Guide to our New Product Pipeline Visualization We're elevating our breakthroughs in a bold new way on Pfizer.com. Check out our new visualized product pipeline, where you'll be able to take a deep dive into our working innovations and see where each product is in development! Find out...
作者: 其实pfizer的pipeline还是挺好的,有Ibrance,jak抑制剂,pd-1抑制剂,PCSK9抑制剂,IDO,OX40。只是可能没有像立普妥这种10billion级别的药王的吧。
[2]Pfizer: Pfizer Pipeline, October 31, 2023 [3]Endpoints News: Pfizer shelves five mid- and early-stage programs [4]Fierce Pharma: Amid COVID slump, Pfizer turns attention to RSV launch and a potential future in obesity [5]Fierce Pharma: UPDATED: Pfizer plans to shutter New Jersey site...
近日读到一篇发表在Drug Discovery Today的综述文章《Reviving an R&D pipeline: a step change in the Phase II success rate》。该文介绍了Pfizer在2010年之后由于面临重磅品种专利悬崖的冲击,迫切需要提高研发成功率,故而在研发战略方面进行了若干变革。10年之后再看,Pfizer的II期成功率整体攀升,从19%提升到了53...
"While we see several assets in Pfizer's pipeline (particularly in oncology) that could make the story more interesting, we believe that further advancement ... will be necessary to change the current narrative on shares which would primarily occur 2026+," JP Morgan analyst Chris Schott wrote ...